10-Q: bioAffinity Technologies Faces Financial Hurdles Despite Revenue Growth
Quarterly Report
bioAffinity Technologies reported a net loss of $5.3 million for Q3 2026, with ongoing concerns about its ability to continue as a going concern, despite a 79% increase in CyPath Lung testing revenue.
Summary
- bioAffinity Technologies reported a net loss of $5.3 million for the three months ended September 30, 2026, and $12.3 million for the nine months ended September 30, 2026.
- Total net revenue decreased by 26% to $1.1 million for Q3 2026 compared to $1.4 million in Q3 2025, primarily due to a decrease in lab revenue.
- CyPath Lung testing revenue increased by 79% to $1.1 million for the nine months ended September 30, 2026, compared to $0.6 million in the same period of 2025.
- The company has an accumulated deficit of approximately $80.8 million as of September 30, 2026.
- Management has concluded there is substantial doubt about the company's ability to continue as a going concern for at least twelve months.
- The company raised $4.0 million in October 2026 and $4.0 million in August 2026 through financings.
Sentiment
Score: 3
Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the continued significant net losses, substantial accumulated deficit, and the explicit statement of substantial doubt about the company's ability to continue as a going concern, despite some revenue growth in specific areas.
Positives
- CyPath Lung testing revenue increased by 79% to $1.1 million for the nine months ended September 30, 2026, compared to $0.6 million in the same period of 2025.
- The number of ordering physicians for CyPath Lung increased by 89% in Q3 2026 compared to Q3 2025.
- The company announced it had regained compliance with Nasdaq listing requirements on September 9, 2026.
- A Hong Kong patent for the CyPath Lung diagnostic platform was granted on September 17, 2026.
- A Japanese patent allowance covering CyPath Lung and its AI-built algorithm was announced on August 8, 2026.
- The company entered into a distribution agreement with AvMEDICAL on August 18, 2026.
Negatives
- The company reported a net loss of $5.3 million for the three months ended September 30, 2026, compared to $5.1 million in the prior year period.
- Total net revenue decreased by 26% to $1.1 million for Q3 2026 compared to $1.4 million in Q3 2025, primarily due to a decrease in lab revenue.
- The company has an accumulated deficit of approximately $80.8 million as of September 30, 2026.
- Cash and cash equivalents decreased to $2.6 million as of September 30, 2026, from $6.4 million at December 31, 2025.
- Management has concluded there is substantial doubt about the company's ability to continue as a going concern for at least twelve months.
- Selling, general and administrative expenses increased by 25% to $2.8 million in Q3 2026 compared to $2.2 million in Q3 2025.
Risks
- The company's business plan relies on its ability to obtain additional sources of capital and financing; failure to do so may require the company to cease operations.
- The company has incurred significant losses and negative cash flows from operations since inception and expects to continue to do so.
- The company may never succeed in developing and commercializing its diagnostic tests and therapeutic products, or may never generate sufficient income to achieve profitability.
- The company needs to raise further capital through the sale of additional equity or debt securities, strategic relationships, or grants to support future operations.
- If the company is unable to improve its liquidity position, it may not be able to continue as a going concern.
- The company has limited experience operating a clinical laboratory and may not accurately estimate incurred expenses.
- The company's future is dependent upon its ability to obtain financing and upon future profitable operations from the development of new business opportunities.
Future Outlook
The company expects to continue to incur significant operating losses for the foreseeable future and anticipates raising additional capital through private or public sales of equity or debt securities, collaborative arrangements, or a combination thereof to fund operations and product development. Management concludes there is substantial doubt about the company's ability to continue as a going concern.
Management Comments
- Management concludes that there is substantial doubt about the Companys ability to continue as a going concern for a period of at least twelve (12) months subsequent to the issuance of the accompanying unaudited condensed consolidated financial statements.
- We need to raise further capital through the sale of additional equity or debt securities or other debt instruments, strategic relationships or grants, or other arrangements to support our future operations unless our revenue increases significantly.
- Our business plan includes expansion for our commercialization efforts which will require additional funding.
- If we are unable to improve our liquidity position, we may not be able to continue as a going concern.
Industry Context
StockSavvy.ai notes that bioAffinity Technologies operates in the competitive diagnostics and therapeutics space, focusing on early-stage lung cancer detection and precision diagnostics for lung diseases. The company's reliance on flow cytometry and AI-driven analysis places it at the forefront of technological advancements in the field, but also requires significant investment in R&D and regulatory approvals.
Comparison to Industry Standards
- The company's revenue growth for CyPath Lung testing (79% for nine months) outpaces some established diagnostic companies, but its overall revenue decline in Q3 2026 due to lab service decreases highlights the volatility in the sector.
- The significant net losses and accumulated deficit are common for early-stage biotech and diagnostic companies investing heavily in R&D and clinical trials, but the explicit going concern warning is a critical factor.
- Competitors in lung cancer diagnostics include companies developing liquid biopsy tests and advanced imaging techniques. bioAffinity's non-invasive sputum-based approach aims to differentiate itself.
- The company's development of precision diagnostics for asthma and COPD aligns with the broader industry trend towards personalized medicine, targeting specific biomarkers for treatment selection.
Legal Proceedings
- To date, the Company has had no material pending legal proceedings.
Stakeholder Impact
- Shareholders may experience a decline in investment value due to the company's financial condition and going concern issues.
- Employees may face uncertainty regarding job security due to the company's financial challenges.
- Creditors and suppliers may face risks related to the company's ability to meet its financial obligations.
Next Steps
- Continue development and commercialization of diagnostic tests and therapeutic products.
- Seek strategic partners for therapeutic development.
- Continue to work with insurance providers to improve reimbursement levels for CyPath Lung.
- Advance the application of CyPath Lung test for surveillance of lung cancer patients.
- Continue enrollment in the CyPath Lung longitudinal clinical trial.
- Develop next-generation diagnostic tests for asthma and COPD in collaboration with Pictor, Inc.
Key Dates
| Date | Description |
|---|---|
| 2024-03-18 | Company entered into a finance agreement to purchase a 2024 Toyota Corolla. |
| 2025-01-10 | Company entered into a second finance agreement to purchase a 2024 Toyota Corolla. |
| 2025-05-22 | Company entered into an at-the-market issuance sales agreement (ATM Agreement). |
| 2025-08-31 | Series B Convertible Preferred Stock investors had converted 840 of 990 shares. |
| 2026-01-01 | Start of the nine months period for financial reporting. |
| 2026-03-31 | End of the first quarter for financial reporting. |
| 2026-04-29 | Company's annual meeting of shareholders approved an amendment to the 2024 Equity Incentive Plan. |
| 2026-09-30 | End of the quarterly period for financial reporting. |
Recommendation
sellThe filing indicates significant financial distress, including substantial net losses, an accumulated deficit, and a stated doubt about the company's ability to continue as a going concern. While there are positive developments in specific product revenues and patent grants, these are overshadowed by the severe financial risks. Investors should consider selling their holdings given the high probability of further financial challenges and potential for significant loss.
Keywords
lung cancer diagnostic, CyPath Lung, flow cytometry, precision diagnostics, asthma, COPD, laboratory services, clinical trial
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.